Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  NANOBIOTIX    NANO   FR0011341205

NANOBIOTIX (NANO)

Delayed Quote. Delayed  - 06/01 09:08:45 am
19.2 EUR   +0.42%
04/29 NANOBIOTIX : 2015 Annual Results
04/29 NANOBIOTIX : 2015 Annual Results
01/05 Nanobiotix starts a new research program, in Immuno Oncology, wit..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

NANOBIOTIX : and the CLARA, partners of ETPN for the organization of the Nano World Cancer Day

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/28/2013 | 08:40am CEST
Nanobiotix and the CLARA, partners of ETPN for the organization of the Nano World Cancer Day

01.28.2013

An event organized by the European Technology Platform of Nanomedicine in the framework of the World Cancer Day

Paris and Lyon, France, January 28th, 2013 - Nanobiotix and the Lyon Auvergne Rhône-Alpes Cancer Research Cluster (CLARA) today announce their participation to the European event on February the 1st organized by ETPN (European Technology Platform of Nanomedicine). Similar events will be organized in parallel across Europe: France, United Kingdom, Germany and Portugal. Nano World Cancer Day is an event organized by the ETPN highlighting the importance of nanomedicine research for cancer on the European level.

"How nanomedicine contributes to better cancer diagnostic and therapy"

Radiotherapy, chemotherapy and surgery are part of the therapeutic arsenal for patients with cancer. New technologies associated with nanoparticles could provide more effective solutions to personalize diagnoses and treat these diseases, while improving targeted drug delivery and reducing side effects and collateral damages on the body. These breakthrough therapies based on nanomedicine contribute to solving this paradigm and are already a reality, with concrete results, 60 nano-products on the market and more than 70 in the pipeline. Nanomedicine can go further in bringing new therapeutic mode of action into cells. For instance, nanoparticles can already be injected into the tumor and then be activated to produce physical effect and destroy cancer cells locally.

Across the parallel European press events, leading international actors in the field will introduce examples highlighting the key role of nanomedicine for cancer therapy, diagnoses and imaging. This year, these actors across Europe are:

National Cancer organizations: CLARA (FR), Comprehensive Cancer Center (Charité University Hospital) (DE), International Iberian Nanotechnology Laboratory (PT) and Instituto Português de Oncologia do Porto (PT).

SMEs: Nanobiotix (FR & DE).

Universities / Public laboratories: Thomas Jefferson University, Philadelphia, US (FR), Université Paris Sud, Institut Galien Paris-Sud / CNRS (FR), Ludwig-Maximilians University München (DE), Aachen University Hospital (DE), Universidad de Santiago de Compostela (Spain), University of Lisboa/ Faculty of Pharmacy (PT), Leeds University (UK).

 Leading local experts involved in the Paris event:

-          Dr. Amaury MARTIN, Secretary General of CLARA (Lyon Rhône-Alpes Auvergne Cancer Research Cluster), Lyon

-          Dr. Laurent LEVY, Vice Chairman ETPN, CEO of Nanobiotix, Paris

-          Pr. Bo LU, MD, Thomas Jefferson University Hospital, Professor in the Department of Radiation Oncology and Director of the department's Division of Molecular Radiation Biology, Philadelphia

-          Pr. Elias FATTAL, Paris Sud University, Institut Galien Paris-Sud, CNRS-UMR 8612, Faculty of Pharmacy, Châtenay-Malabry.

This conference will give an overview on nanomedicine for cancer: what are the key areas of research? What are the new methods of diagnosis? What are the new treatments in development? What are the first results? What are the products used every day?

Videos of the Paris event will be available on February the 4th 2013 for the World Cancer Day.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on NANOBIOTIX
04/29 NANOBIOTIX : 2015 Annual Results
04/29 NANOBIOTIX : 2015 Annual Results
01/05 Nanobiotix starts a new research program, in Immuno Oncology, with its lead p..
01/05 NANOBIOTIX : starts a new research program in Immuno Oncology with its lead prod..
01/04 NANOBIOTIX : FDA approved Investigational New Drug for NBTXR3 in a new clinical ..
01/04 NANOBIOTIX : FDA approved Investigational New Drug for NBTXR3 in a new clinical ..
2015 NANOBIOTIX : Soft Tissue Sarcoma pivotal trial progressing well as planned: alre..
2015 NANOBIOTIX : Soft Tissue Sarcoma pivotal trial expands dynamically as planned: a..
2015 NANOBIOTIX : Releases Half Year Results for the 6 Months Ended 30 June
2015 NANOBIOTIX : Posts Half Year Results for the 6 Months Ended 30 June 2015
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials